Open AccessEffects of intravenous sm‐9527 (double‐chain tissue plasminogen activator) on left ventricular function in the chronic stage of acute myocardial infarction
Author(s) -
Hayashi Hiroshi,
Yamauchi Kazunobu,
Saito Hidehiko,
Takatsu Fumimaro,
Osugi Junichi,
Sone Takahito,
Mizutani Noboru,
Watanabe Tsutomu,
Hirayama Haruo,
Ogawa Hirokazu,
Yamada Kazuo
Publication year - 1993
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960160508
Subject(s) - medicine , myocardial infarction , cardiology , fibrinolysis , tissue plasminogen activator , stage (stratigraphy) , infarction , paleontology , biology
Clinical effects of thrombolytic agent SM‐9527 (double‐chain tissue plasminogen activator) on left ventricular (LV) function were assessed in patients with acute myocardial infarction (AMI). A dose of 30 × 10 6 IU SM‐9527 was given intravenously to patients with AMI within 6 h after onset Of 159 candidates, 20 were excluded from the trial due to diseases other than myocardial infarction or failure to meet the protocol requirements; 114 of the remaining 139 were subjected to LV function analysis. The following results were obtained: (1) Patients with successful reperfusion in response to SM‐9527 in the acute stage without later reocclusion revealed a significant improvement of LV function in the chronic stage. (2) Adverse effects were noted in 15 patients (10.8%), but none were serious; all were bleeding related to catheterization. (3) Hemagglutination fibrinolysis system test revealed no problems. It is concluded that early thrombolytic therapy with intravenous SM‐9527 for AMI provides significant improvement of LV function in the chronic stage.